Geneva (awp) – The Vaud Ferring laboratory has obtained the green light from the United States Health Agency (FDA) for its fecal microbiota Rebyota, intended to prevent the resurgence of infections induced by the bacterium Clostridium difficile. Administration of Rebyota to patients over the age of 18 remains subject to prior full antibiotic treatment.
Administered rectally in a single dose, the treatment is prepared from the excreta of qualified donors, thoroughly tested for a range of transmissible pathogens. However, the origin of the product cannot exclude a risk of transmission of infectious agents, specifies the gendarme of medicines on its website.
Ferring, for his part, says he’s conducted no fewer than five clinical trials, involving more than 1,000 patients, without noticing any serious side effects.
jh/al
